VINCERX PHARMA
We derive our name from the latin word vincēre meaning
“to conquer”.
We aspire to conquer cancer with innovative therapies.

Our Vision

To address the unmet medical needs of our patients with paradigm-shifting therapeutics.

Clinical
Program

VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer.

Pipeline

VINCERX PHARMA
NEWS

Vincerx Pharma Announces $50 Million Private Placement

Strengthened financial position extends expected cash runway into 2023 PALO ALTO, Calif. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma , Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics,

Menu